ClinicalTrials.gg
Not yet recruitingNCT07179003Updated Aug 19, 2026

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

A Phase 2 interventional study of Standard of care breast abscess drainage and Methylene Blue in Breast Abscess, sponsored by University of Rochester. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by University of Rochester · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Abscess with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Abscess · United States.

Planned enrollment
53rd of 75
50 · median 114
Started
2027
with 1 other
Phase 2
16 of 80
3 open now
Registered
79th of 80
by date
Lead sponsor
3 of 80
University of Rochester

Among the 80 studies in Abscess with a site in United States, this one is the 53rd largest by planned enrollment of the 75 interventional ones that give a count, is one of 2 that started in 2027, is one of 16 in phase 2, and was the 79th registered.

Abscess

152 studies on the registry are indexed under Abscess; 22 are open to participants now.

Browse Abscess studies →

Open to participants now

4 of the 80 studies in Abscess with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Abscess studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Abscess with a site in United States, or all of them as a file.
02

Study summary

The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous breast abscess drainage for disinfection of breast abscesses. The study includes two arms: (1) standard of care breast abscess drainage and (2) MB-PDT plus standard of care breast abscess drainage. The primary endpoint is time to resolution of clinical symptoms. Secondary endpoints include imaging evidence of abscess resolution, abscess recurrence, need for repeated intervention, and cure rate across treatment groups. Responses will be compared between the two study arms for the per protocol population to determine the efficacy of MB-PDT relative to standard of care. The investigators hypothesize that the addition of MB-PDT to standard of care will significantly reduce the time to symptom resolution, compared to standard of care alone.

Read the detailed description

Breast abscesses consist of a localized, walled-off collection of infected fluid within the breast, with symptoms including breast pain and inflammation, as well as nipple discharge, fever, chills, and nausea. If left untreated, breast abscesses can result in serious complications, including fistula formation and sepsis. The standard of care therefore involves draining the purulent fluid, generally under ultrasound guidance, and systemic antibiotic administration. Although this drainage procedure is typically technically successful, reported recurrence rates vary widely. These recurrent breast abscesses can require repeated drainage procedures, surgical intervention, extended hospital stays, and aggressive antibiotic regimens.

Photodynamic therapy (PDT), which relies upon the combination of photosensitive dyes known as photosensitizers, excitation by visible light, and molecular oxygen to generate bactericidal reactive oxygen species, represents a potentially powerful adjunct to standard of care drainage. The investigators have successfully completed a Phase 1 clinical trial assessing the safety and feasibility of methylene blue (MB) PDT at the time of percutaneous intra-abdominal abscess drainage. No adverse or serious adverse events were observed, and the procedure was well tolerated by all subjects. Based on the success of this Phase 1 clinical trial, the current study aims to assess efficacy of MB-PDT at the time of breast abscess drainage.

The investigators propose a randomized, controlled Phase 2 clinical trial, which will be conducted in accordance with the principles of good clinical practice and with approval by both the FDA and local IRB. Patients who have been diagnosed with a drainable abscess, that meet all inclusion/exclusion criteria, and have the approval of their primary care team, will be offered enrollment in the study at initial presentation. Consented subjects will be prospectively randomized using block randomization to one of two arms: (1) standard of care (SOC) percutaneous drainage and antibiotics alone or (2) PDT + SOC. The primary outcome is time to resolution of clinical symptoms. The secondary outcome is imaging evidence of abscess resolution, based on ultrasound tomography. Tertiary outcomes include abscess recurrence, need for repeated intervention, and cure rate across treatment groups.

The study population will consist of 50 subjects, allocated equally between the two groups. Sample size calculations are based on a hypothesized reduction in the time to resolution of clinical symptoms. The investigators use retrospective data from patients that received SOC at our institution over the course of 15 years to represent SOC, and the 18 subjects treated in our Phase 1 clinical trial in abdominopelvic abscesses to represent PDT. Retrospective standard of care patients had median time to resolution of 16 days (95% CI 14-18 days), while subjects treated with MB-PDT had a median time to resolution of 7 days (95% CI 3-14 days). This corresponds to a hazard ratio for resolution of symptoms of 3.5. The investigators target 90% power at a more conservative hazard ratio of 3.0 to determine the sample size in each arm. A sample size of 25 subjects per arm provides 90% power to detect a hazard ratio of 3.0 at a two-sided alpha=0.05 level of significance. With equal allocation between groups, this results in a total sample size of 50 participants, given that the investigators assume to fully observe the primary outcome in all subjects.

All subjects will receive standard of care ultrasound-guided percutaneous breast abscess drainage. The site will be prepared and dressed following standard of care sterile procedure, and a needle will be advanced under ultrasound guidance into the abscess. The abscess will be drained by syringe aspiration, and the cavity will be flushed with sterile saline. Aspirated abscess fluid will be delivered to the Clinical Microbiology Laboratory for processing.

For subjects randomized to the PDT arm, sterile methylene blue (MB) will then be administered to the abscess cavity using the same needle/catheter utilized for standard of care drainage. After a 10-minute incubation interval, MB will be aspirated and the cavity flushed with sterile saline. The abscess cavity will then be filled with sterile 0.1% lipid emulsion to gently distend the cavity, and through light scattering, homogenize the light dose to the walls of the cavity. A sterile optical fiber will be advanced to the approximate center of the abscess cavity via the same catheter/needle used for standard of care under image guidance. The proximal end of the fiber will be coupled to the output of a clinical laser system emitting light at 665 nm. Laser power will be delivered to the cavity at a constant fluence rate of 20 mW/cm\^2. The laser power required to obtain the desired fluence rate at the wall will be calculated based on the abscess size. Illumination will be delivered for \~20 minutes, resulting in a total delivered fluence of 25 J/cm\^2.

Immediately after laser irradiation, the Intralipid solution will be aspirated and the cavity again flushed with sterile saline. SOC drainage will then be completed, including cleaning of the skin surface and wound dressing.

All subjects will receive ultrasound tomography of their affected breast using an FDA-approved ultrasound tomography system located at our institution. This will be performed immediately pre- and post-intervention (SOC or PDT+SOC), and at follow-up appointments. From these images, the investigators will first extract the abscess volume and viscosity of the infected fluid on pre-procedure imaging. At each timepoint, abscess volume, abscess wall stiffness and density, and surrounding breast tissue stiffness and density will be extracted from imaging data.

A Cox proportional hazards model will be used to model time to clinical symptom resolution. A 1-degree of freedom likelihood ratio test comparing time to resolution between the control group (SOC alone) and the PDT group (PDT+SOC) will be used for the primary analysis. Abscess recurrence and need for repeated intervention will be compared between treatment groups using a Cox proportional hazards model. Cure rate will be compared between groups using Fisher's exact test. Imaging outcomes (breast abscess volume, density, stiffness) will be compared between groups using linear mixed-effects models, and will further be compared to radiologist measurements using Wilcoxon matched-pairs signed rank tests. Multivariable Cox proportional hazards models will be used to examine the effects of anatomical features, risk factors, and subject demographics on long-term treatment responses.

If successful, this research could demonstrate efficacy of PDT as an adjunct treatment for breast abscess patients that significantly reduces time to symptom resolution. The investigators hypothesize that this could also lead to reduced abscess recurrence. Ultimately, this would promote early recovery, reduce repeated intervention, and lead to lower overall health care costs for patients undergoing ultrasound-guided percutaneous breast abscess drainage.

03

Conditions studied

  • Breast Abscess

Browse trials for

Keywords

  • Breast abscess
  • Drainage
  • Photodynamic therapy
  • Methylene blue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years or older
  • Clinical signs of breast abscess, including pain, redness, and/or heat of the breast
  • Approval by the primary care team to pursue PDT and discuss enrollment with the patient

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Allergy to contrast media, narcotics, sedatives, atropine or eggs
  • Necrotic tissue that requires surgical debridement
  • Severely compromised cardiopulmonary function or hemodynamic instability
  • Thrombocytopenia (\<50,000/mm3)
  • Uncorrectable coagulopathy
  • Poor kidney function (serum creatinine >3mg/dl)
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Patients with hidradenitis suppurativa
  • Patients with granulomatous mastitis
  • Unable or unwilling to understand or to provide
  • Unable or unwilling to undergo study procedures
  • Patient unable to cooperate with, or to be positioned for the procedure
  • Unable to comply with necessary follow up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    MB-PDT + standard of care

    Each subject in this arm will receive standard of care breast abscess drainage, methylene blue, lipid emulsion, and laser illumination.

    Procedure: Standard of care breast abscess drainage · Drug: Methylene Blue · Drug: Lipid Emulsion · Device: Insertion of optical fiber · Device: Laser illumination · Procedure: Photodynamic therapy

  • Other
    Standard of care

    Each subject in this arm will receive standard of care abscess drainage

    Procedure: Standard of care breast abscess drainage

Interventions

  • ProcedureStandard of care breast abscess drainage

    All subjects will receive ultrasound-guided percutaneous abscess drainage in a procedure room. The site will be prepared and dressed following standard of care sterile procedure, and a needle/catheter will be advanced under ultrasound guidance into the abscess. The abscess will be drained by syringe aspiration, and the cavity will be flushed with sterile saline. Aspirated abscess fluid will be delivered to the Clinical Microbiology Laboratory for processing, including bacterial identification and antibiotic susceptibility testing.

  • Following standard of care breast abscess drainage, for subjects randomized to the photodynamic therapy arm, sterile, clinical-grade methylene blue will be infused into the abscess cavity at a concentration of 100 µg/mL via the same needle/catheter used for drainage. The volume introduced will be matched to the amount of abscess material aspirated during the standard of care drainage. After a 10-minute incubation interval, methylene blue will be aspirated and the cavity flushed with sterile saline to remove methylene blue that has not been taken up by microbes.

  • DrugSoybean OilStudies of Soybean OilSoybean Oil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For subjects randomized to the photodynamic therapy arm, immediately prior to illumination a lipid emulsion will be administered directly to the abscess through the drainage needle/catheter at a concentration of 0.1%. This lipid emulsion will be either Intralipid or Nutrilipid. The lipid emulsion serves to gently distend the cavity, and through light scattering, homogenize the light dose to the walls of the cavity. The volume administered will be matched to the amount of abscess material aspirated during the standard of care drainage. Following laser illumination, the lipid emulsion will be aspirated and the cavity flushed with sterile saline.

  • DeviceInsertion of optical fiber

    For subjects randomized to the photodynamic therapy arm, a sterile, single-use optical fiber will be advanced to the approximate center of the abscess cavity via the same needle/catheter used for abscess drainage under ultrasound guidance. This will be connected to the clinical laser system via SMA connector for delivery of treatment light.

  • DeviceLaser illumination

    For subjects randomized to the photodynamic therapy arm, laser illumination for photodynamic therapy will be delivered by a laser system operating at 665 nm (ML7710, Modulight, Tampere, Finland) at a fluence rate of 20 mW/cm\^2. The laser power required to achieve this fluence rate will be calculated based on abscess size. Illumination will be delivered for \~20 minutes, resulting in a total delivered fluence of 25 J/cm\^2.

  • ProcedurePhotodynamic therapy

    For subjects randomized to the photodynamic therapy arm, the photodynamic therapy procedure comprises the methylene blue, lipid emulsion, insertion of optical fiber, and laser illumination interventions.

06

What researchers measure

Primary outcomes

  1. Time to resolution of clinical symptoms

    Clinical symptoms will be scored daily using a standardized questionnaire that includes objective measures of fever, heart rate, and blood pressure, as well as subjective ratings of pain and heat of the breast using a Likert score. Time to resolution of clinical symptoms will be defined as the time from intervention to the first day on which subjects are afebrile and report no pain, redness, or heat of the breast.

    Time frame: Day 1 post-intervention until resolution of symptoms

Secondary outcomes

  1. Abscess volume on ultrasound tomography

    All subjects will receive ultrasound tomography of their breast immediately prior to abscess drainage, immediately following drainage, and at follow-up appointments. Follow-up imaging will occur at 14 days post-drainage, and every 14 days thereafter until abscess resolution. Images will be segmented to identify the abscess cavity and measure its volume in mL.

    Time frame: Day 14 post-intervention until resolution

Other outcomes

  1. Time to abscess recurrence

    Each subject's electronic medical record will be reviewed at 6 months post-intervention to determine whether there was recurrence of the treated abscess. If there was recurrence, time to recurrence in days will also be recorded.

    Time frame: 6 months post-intervention

  2. Time to repeated intervention

    Each subject's electronic medical record will be reviewed at 6 months post-intervention to determine whether additional procedures were required to manage the treated abscess. If repeated intervention was required, the time from study intervention to repeated intervention in days will also be recorded.

    Time frame: 6 months post-intervention

  3. Rate of abscess cure

    Each subject's electronic medical record will be reviewed at 6 months post-intervention to determine whether there was recurrence of the treated abscess, whether additional procedures were required to manage the treated abscess, and whether clinical symptoms resolved. If over this 6-month period there was no recurrence, no additional procedures were required to manage the abscess, and clinical symptoms resolved, this will be classified as a cure. If any of these conditions are not satisfied, this will be classified as not cured.

    Time frame: 6 months post-intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2027; primary completion for Jun 2032, 59 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 17, 2025
StartEst.
Jul 2027
Primary completionEst.
Jun 2032
CompletionEst.
Jun 2032
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07179003
Responsible party
Timothy Baran (Assistant Professor, University of Rochester) — Principal investigator
First posted
Sep 17, 2025
Start date
Jul 2027 (estimated)
Primary completion
Jun 2032 (estimated)
Completion
Jun 2032 (estimated)
Last update
Aug 19, 2026

Study contacts

Timothy M Baran, PhD
Contact
timothy_baran@urmc.rochester.edu
585-276-3188
Anna Weiss, MD
Contact
585-487-1700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylene Blue

Start the discussion